Clinical Data CLDA
-
Why 2011 Could Be a Big Year for Pharmaceutical M&A
VFC submits: Just a couple of weeks after Gilead Sciences ( GILD ) announced that it would be raising the prices of its leading HIV drugs, the company issued first quarter earnings numbers that were significantly below analyst expectations. The two events are most likely largely unrelated, however,
-
Russell 2000 at Highest Level Since 2007
Value Expectations submits: The Russell 2000 index, the most common benchmark for small-cap stocks, ended a strong week last week gaining 3% and ending at its highest level in 3 ½ years. Year to date, the small cap index has gained over 7%, just above the YTD returns on Dow Jones Industrial Average
-
Optimer Pharma: Prime Acquisition Target
TheMarketFinancial submits: In February, Clinical Data ( CLDA ) won a surprising approval for its flagship product ..... lead to Optimer Pharmaceuticals ( OPTR ). Much like Clinical Data ’s recently approved viibryd, Optimer’s flagship …
-
Clinical Data Inc.: Is $30 the Floor?
… announced Forest Laboratories’ ( FRX ) acquisition of Clinical Data Inc. ( CLDA ) strongly suggests that this merger is far from ..... happened to cause such outrage? On January 24, 2011, Clinical Data ’s Viibryd (vilazodone) was approved for the …
-
Clinical Data and Forest Labs Agree to Split the Risk
… Stephen D. Simpson, CFA The tug of war between Clinical Data ( CLDA ) bulls and bears has ended in what has to be called a draw. Flying in the face of the bear argument that Clinical Data 's recently-approved depression drug Viibryd is …
-
Extending Its Reach in the Anti-Depressant Market, Forest Announces Acquisition of Clinical Data
… Laboratories FRX announced an agreement to acquire Clinical Data CLDA for $1.2 billion net of cash plus contingent consideration ..... company's cash pile quickly. Forest's interest in Clinical Data largely surrounds its recently approved anti-depressant …
-
Forest Laboratories (FRX) to acquire Clinical Data ( CLDA ) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced ...
Forest Laboratories ( FRX ) to acquire Clinical Data ( CLDA ) for $30/share in cash and another $6/share on milestones ..... deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder …
-
Premarket gainers: [[HNSN]] +42%. [[FRG]] +38%. [[SFLY]] +17%. [[GMCR]] +17%. [[BJ]] +14%. [[NETL]] +10%. [[ENTR]] +7%. [[PSTI]] +5%. [[ CLDA ]] +5%. [[LTD]] +5%. [[JCP]] +4%. [[KEM]] +4%. [[TTM]] +4%. ...
… Premarket gainers: HNSN +42% . FRG +38% . SFLY +17% . GMCR +17% . BJ +14% . NETL +10% . ENTR +7% . PSTI +5% . CLDA +5% . LTD +5% . JCP +4% . KEM +4% . TTM +4% . BX +4% . APKT +4% . YUM +4% . Losers: ANW -12% . TZOO …
-
Clinical Data : Incredible Potential Even After a 50% Pop
… after it pops 50%. As we now know, the FDA approved Clinical Data 's ( CLDA ) drug Vilazodone after the markets close 2 Fridays ..... top of the trendline is around $40 at this time. CLDA has vaulted above the previous trendline and may be …
-
Eight underperforming stocks with increasing put/call ratios, according to Kapitall: Clinical Data ( CLDA ), Home Inns & Hotels (HIHM), Supervalu (SVU), Volcom (VLCM), Orbitz (OWW), Ctrip.com (CTRP), ...
Eight underperforming stocks with increasing put/call ratios, according to Kapitall: Clinical Data ( CLDA ), Home Inns & Hotels ( HIHM ), Supervalu ( SVU ), Volcom ( VLCM ), Orbitz ( OWW ), Ctrip.com ( CTRP ), Clearwire ( CLWR …